Introduction
In many studies, it is assumed that data obtained from research involving male participants could be extrapolated to women, although it could be demonstrated that sex “can account for high (50%–75%) inter-individual variability in pharmacological responses”.1–5 A recently published article could show a sex bias against female participants in articles, being highest for studies on chronic kidney diseases (CKDs) compared with other diseases (global female prevalence of CKD 0.57, female participant fraction of the compared studies on CKD 0.40).6 The sex bias is still present in the majority of research disciplines despite research policies.6 7 Relevant under-representation of female participants could be made transparent by a recent study focussing on HIV/AIDS, CKD and cardiovascular diseases among others.6 The under-representation of female sex applies not only for study population involving disease diagnosis but also for scoring systems, like severity and nursing scores for intensive care unit (ICU) treatment (Therapeutic Intervention Scoring System (TISS-28), Simplified Acute Physiology Score (SAPS), Nine Equivalents of Nursing Manpower Use Score (NEMS)).8–10
Moreover, the epidemiology and outcome of many diagnoses are related to biological sex.11 The Global Burden of Disease Study estimated that CKD deaths among men of all ages were 14.5 per 100 000, whereas in women they were 12.14.12 Sex has been shown to influence medical diagnoses.7 13 Not only the biological but also other different determinants from social and economic to individual behaviours of patients and providers possibly contribute to the reported differences.14
Kidney disease (KD) is a particularly relevant disease with sex differences. There are more women with CKD, yet only 40% of patients receiving kidney replacement therapy are female.12 15–17 In the dialysis population, the percentage of women is less than 50%, for both prevalent and incident patients.12 When calculating the life expectancies of men and women (age 30–85 years), it could be shown that under the presumption that women generally live longer than men they actually lived 1–2 years less than men with both groups having CKD stage 5.12 Disparities in access to care are also described for ICU admission, less aggressive medical care and later initiation of renal replacement therapy.18–20 Even in high-income countries, the access to kidney transplantation seems to be limited for women and they receive less and donate more organs.12 19 Globally, CKD stage 5 without renal replacement therapy was estimated to be present in the same number of women and men (3.2 million), but 1.3 million female and 1.7 million male patients were treated with dialysis and 0.3 million female versus 0.4 million male patients had a functioning kidney graft.16 The lacking treatment corresponds to outcomes of CKD as well as of acute kidney injury (AKI).11 16 17 19 21
Biological sex is recognised as modulator of the course and progression of disease and management of CKD. This also has been examined in hospital-acquired AKI (HA-AKI).16 22–24 The introduction of the KDIGO guidelines (2012 KDIGO Clinical Practice Guideline for AKI and the Clinical Practice Guideline for the Evaluation and Management of CKD25 26) to assess AKI and CKD raised questions concerning sex differences due to definition criteria.23 24 27 Whatever the concluding discussion will convey in the future, there is no doubt that for both sex the prevalences are high, with AKI ranging from 10.7% to 31.3%,15 28 29 that sex differences in epidemiology and the transition from AKI to CKD can be observed22 30 and that HA-AKI is associated with increased mortality.31–35 Moreover, for both sexes AKI, CKD and acute-on-chronic KD are very relevant as a comorbidity, intercurrent disease or complication.28 36 37
Indexing clinical information to diagnosis-timing, that is, using a present-on-admission flag for hospital admission is important in order to monitor complications and disease progression in CKD and AKI. The use of routinely collected health data of inpatient care for understanding patterns of different outcomes has been limited in Switzerland by the fact that pre-existing and postadmission conditions have been indistinguishable.
The use of a ‘Present On Admission Indicator’ (POA) allows to differentiate diagnoses arising during from those arising before an inpatient stay and therefore provides an important perspective on the quality of healthcare provided.
The POA indicator is dependent on the prevalence of the underlying diagnoses and the associated coding guidelines.38 ,39 Therefore, we preferred a data-driven approach to assign diagnoses of AKI, CKD and acute-on-chronic KD with the help of a complex rule engine implementing the KDIGO criteria for diagnosis and staging.25 26
Since 2017, AKI and CKD have been coded according to the KDIGO guidelines in Switzerland,39 but documentation of the exact KDIGO staging is often missing in the electronic health records and coding and documentation quality remains to be an issue.40 POA reporting was introduced into the standard coding process at this study’s institution in 2018.
The aim of this retrospective observational study is to demonstrate the capability of POA reporting with regard to differences in diagnosis groups and sex.